Product-safety considerations in allogeneic chimeric antigen-receptor T-cell process flows

Area of Science:

• Biotechnology
• Cellular Therapy
• Immunotherapy

Background:

• Allogeneic chimeric antigen-receptor T-cell (CAR T) therapies utilize donor cells for broad patient application.
• Current manufacturing involves traditional biologics steps and novel methods like electroporation.
• These processes generate large-scale, single-batch products for treating numerous patients.

Purpose of the Study:

• To outline the process flows for allogeneic CAR T therapy manufacturing.
• To identify and address the unique safety considerations in these evolving processes.
• To emphasize the importance of regulatory compliance and quality by design in ensuring process safety.

Main Methods:

• Description of large-scale primary cell culture techniques.
• Integration of traditional cell expansion and novel electroporation methods.
• Application of regulatory guidelines and quality by design principles.

Main Results:

• Characterization of diverse unit operation-specific safety considerations.
• Highlighting the unique and evolving nature of combined process safety challenges.
• Demonstration of control strategy design for process safety assurance.

Conclusions:

• Robust control strategies are essential for safe allogeneic CAR T manufacturing.
• Quality by design principles are critical for integrating safety into process development.
• Adherence to regulations and proactive safety design are key to advancing cell therapies.